Drug Safety
Glulisine is a safe and effective treatment for type 1 diabetes
Published in Obesity and Diabetes Week, February 13th, 2006
According to recent research published in the journal Hormone and Metabolic Research, "Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfill the mealtime (bolus) insulin requirement in patients with diabetes."
M. Dreyer and colleagues at Bethanien-Krankenhaus GmbH explained, "The aim of this multinational, multicenter, controlled, open-label, randomized, parallel-group study was to compare the efficacy and safety of insulin glulisine (glulisine) to that of insulin lispro (lispro) in adults diagnosed with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Improved insulin resistance after weight loss is not linked to adiponectin changes - Diet & Nutrition
Long-chain polyunsaturated fatty acid diet may protect obese against metabolic syndrome - Drug Safety
Orlistat and micronized fenofibrate are safe and effective for overweight and obese - Obesity Therapy
(+)-Z-BDDA may have applications in treating obesity and metabolic syndrome complications - Type 2 Diabetes
Vaspin expression in adipose tissue may be linked to obesity and type 2 diabetes - Anesthesia
Anesthesia can cause sustained hyperglycemia in C57/BL6J mice - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
